生物标志物 生物标志物
Sriram Jayabal1, Ali R Khan1, Edward A Fon2
1Western University, London, ON, Canada.
Alzheimer's & dementia : the journal of the Alzheimer's Association
|December 25, 2025
概括
通过整合先进的人类相关模型和开放科学原则,TRIDENT增强了神经退行性疾病药物开发. 这种方法旨在提高临床前试验的成功率,加快有效治疗方法的发现.
科学领域:
- 神经科学是一个神经科学.
- 翻译医学是一种翻译医学.
- 药物发现 药物发现 药物发现
背景情况:
- 像阿尔茨海默氏症和帕金森症这样的神经退行性疾病是复杂的,不太了解,并对全球健康和经济造成重大负担.
- 目前的中枢神经系统 (CNS) 药物开发面临高临床试验失败率 (92%) 由于问题,如非人类相关的措施和糟糕的可复制性.
- 需要改善临床前方法,以提高神经退行性疾病候选药物的预测有效性.
研究的目的:
- 引入TRANSlational Initiative to DE-risk NeuroTherapeutics (TRIDENT) 平台,旨在解决神经退行性疾病临床前评估中的关键差距.
- 提高神经退行性疾病药物发现中临床前和临床结果的预测有效性.
- 通过开放科学原则,促进临床前研究的包容性,协作和可重复性.
主要方法:
- 特里登集成了人造多能干细胞 (iPSCs) 和器官,人性化小鼠模型和小鼠模型到一个统一的平台上.
- 该平台利用与人类相关的,基于触摸屏的小鼠和海豚的认知任务,这些任务非常适合人类认知.
- TRIDENT结合了基于性别的分析 (SBA) +和开放科学原则,在麦吉尔大学,多伦多大学和CAMH多个地点验证.
主要成果:
- 特里登特平台为开发有效的神经退行性疾病疗法提供了一种新的解决方案.
- 它最大限度地提高了预测有效性,从而降低了药物发现和开发过程中的风险.
- 目前的评估重点是针对α-synucleinopathies和阿尔茨海默病的化合物,以验证平台的有效性.
结论:
- 特里登特准备彻底改变神经退行性疾病的临床前测试方法.
- 该平台旨在使药物发现过程对制药和生物技术行业更具吸引力.
- 预计这一举措将加速对神经退行性疾病的有效治疗和治疗方法的识别.
相关概念视频
01:20Blood Studies for Cardiovascular System I: Cardiac Biomarkers
749
Cardiac biomarkers are enzymes, proteins, and hormones released into the blood when cardiac cells are injured. They are powerful tools for triaging.
The essential diagnostic tools for detecting myocardial necrosis and monitoring individuals suspected of having acute coronary syndrome (ACS) include:
Troponins
Troponins, particularly cardiac troponins I and T, are the most precise and sensitive markers of myocardial injury. They are detectable within 4-6 hours of myocardial injury and remain...
The essential diagnostic tools for detecting myocardial necrosis and monitoring individuals suspected of having acute coronary syndrome (ACS) include:
Troponins
Troponins, particularly cardiac troponins I and T, are the most precise and sensitive markers of myocardial injury. They are detectable within 4-6 hours of myocardial injury and remain...
749
01:19Blood Studies for Cardiovascular System II: CRP, Hcy, and Cardiac Natriuretic Peptide Markers
516
Cardiac biomarkers are critical in diagnosing, prognosing, and managing cardiovascular diseases. Routine measurement of specific biomarkers such as B-type natriuretic peptide (BNP), C-reactive protein (CRP), and homocysteine (Hcy) is common practice in clinical settings to evaluate heart function and predict cardiovascular events.
These markers indicate stress or strain on the heart muscle:
Natriuretic Peptides (BNP)
Cardiac myocytes produce these hormones in response to ventricular stretching...
These markers indicate stress or strain on the heart muscle:
Natriuretic Peptides (BNP)
Cardiac myocytes produce these hormones in response to ventricular stretching...
516